Last reviewed · How we verify

NCT05021887

A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

Status unknown Phase 1 Last updated 26 August 2021
What this trial tests

Phase 1 trial testing Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals in Asthma in 50 participants. Status unknown.

Timeline
13 August 2021
Primary endpoint
30 September 2021
30 November 2021

Quick facts

Lead sponsorRespirent Pharmaceuticals Co Ltd.
PhasePhase 1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposeother
Enrollment50
Start date13 August 2021
Primary completion30 September 2021
Estimated completion30 November 2021
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

Respirent Pharmaceuticals Co Ltd. — full company profile →

Who can join

Adults 18 to 60, any sex, with Asthma or Bioequivalence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bioequivalence study between two inhaler products of ffluticasone propionate inhalation powder

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other Respirent Pharmaceuticals Co Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05021887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing